YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)

PML


AddThis Social Bookmark Button

Progressive Multifocal Leukoencephalopathy

Progressive Multifocal Leukoencephalopathy (PML) is an irregular disorder of the nervous system that mainly affects individuals with suppressed immune systems (including, allograft recipients such as kidney transplant patients; patients with cancers such as leukemia or lymphoma; and approximately 10% of patients with acquired immune deficiency syndrome (AIDS).

The disorder, which is caused by a frequent human polyomavirus, JC virus, is characterized by demyelination or destruction of the myelin sheath that covers nerve cells. The myelin sheath is the fatty covering, which acts as an insulator on nerve fibers in the brain.

Some prescription medications that treat Multiple Sclerosis have been found to cause Progressive Multifocal Leukoencephalopathy (PML). There have been reports of people suffering PML (Progressive Multifocal Leukoencephalopathy), while taking Avonex and Tysabri.

In many circumstances both Avonex and Tysabri are taken together by those who suffer from multiple sclerosis. Tysabri was withdrawn from the market after 2 recent reports of serious side effects among patients who used it along with Avonex. In one instance, the person died, while in another, the person developed a suspected case of progressive multifocal leukoencephalopathy, a rare and frequently fatal disease of the central nervous system.

PML often results in irreversible neurological deterioration and death. Both patients had taken Avonex for more than two years in combination with Tysabri, the two drugs manufacturers said. Other symptoms of PML consist of mental deterioration, vision loss, paralysis, speech disturbances, ataxia (inability to coordinate movements), and comas. In rare cases, seizures can happen. The worst side effect includes death, which occurs for the most part between 1 and 4 months after onset. But, in some circumstances, survival lasts months to years. 

Progressive in PML means that it continues to get worse and often leads to serious brain damage. Multifocal means that the JC virus causes disease in several different parts of the brain. Leukoencephalopathy indicates that the disease affects the white matter of the brain. More specifically, the JC virus infects cells in the brain called oligodentrocytes. These cells are responsible for producing myelin, a fatty substance that helps protect nerves in the brain. When too much myelin is lost and not replaced by oligodentrocytes, the nerves become damaged and over time stop working properly.

If you or a loved one has taken prescription medications that treat Multiple Sclerosis and were diagnosed with Progressive Multifocal Leukoencephalopathy (PML), please fill out the form at the right for a free case evaluation by a qualified defective drug attorney.

Biotech firms' drug is linked to deaths

Dec 19, 2006 | Los Angeles Times
The bestselling medicine for two of the country's biggest biotech drug companies has been further linked to a rare and deadly brain infection, U.S. health officials warned Monday. The news could hurt efforts by Genentech Inc. and Biogen Idec Inc. to expand approved treatments for Rituxan. Patients taking Rituxan, a drug approved to treat rheumatoid arthritis and non-Hodgkins lymphoma, have been known to contract the rare brain infection. But two patients being treated for lupus also have died...

Biogen, Genentech issue warning for Rituxan

Dec 19, 2006 | www.cbsmarketwatch.com
Biogen Idec and Genentech have issued a warning to healthcare providers for their oncology drug Rituxan, advising them that the drug has been linked to the deaths of two lupus patients from a rare brain disease. According to an advisory sent out by the Food and Drug Administration early Tuesday, Biogen  and Genentech have sent a letter to healthcare providers informing them that two lupus patients taking Rituxan died of the rare brain disorder PML, an illness generally seen in patients...

Rituxan (rituxamab) Linked to Two Deaths in Lupus Patients

Dec 19, 2006 | www.medpagetodaycom
Two patients treated with the immune modulator Rituxan (rituximab) for systemic lupus erythmatosus (SLE) have died of progressive multifocal leukoencephalopathy (PML), the FDA warned physicians. The FDA said that PML, a viral infection of the central nervous system, has been reported in patients as late as 12 months after their last dose of Rituxan. PML is caused by reactivated JC virus which is present in about 80% of adults. SLE is not an approved indication for Rituxan. It is indicated for...

Off-Label Use of Rituxan Linked to Fatal Leukoencephalopathy

Dec 19, 2006 | www.medscape.com
The US Food and Drug Administration (FDA) is warning healthcare professionals regarding the risk for progressive multifocal leukoencephalopathy (PML) in patients receiving rituximab intravenous infusion (Rituxan, made by Genentech, Inc, and Biogen Idec, Inc) for the treatment of systemic lupus erythematosus (SLE), an off-label indication. The warning was based on 2 fatal cases of PML in patients with SLE receiving rituximab, according to an alert sent today from MedWatch, the FDA's safety...

Rituxan warning issued by FDA

Dec 19, 2006 | North County Times
Patients treated with Rituxan may be at risk from a rare, fatal brain infection, the U.S. Food and Drug Administration warned Monday. The FDA said it has recently learned of two deaths from progresive multifocal leukoencephalopathy (PML) in patients treated with Rituxan, a drug developed in San Diego by Idec Pharmaceuticals, now merged with Biogen to form Cambridge-based Biogen Idec. The patients were given Rituxan, for systematic lupus erythematosus, or SLE. Rituxan is not approved to treat...

More PML News

Progressive Multifocal Leukoencephalopathy
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

If you believe PML is due to an Multiple Sclerosis drug, please list drug:

Please describe your case:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | ReNu with MoistureLoc | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2008 YourLawyer.com. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News